Haleon PLC Sponsored ADR ( (HLN) ) has released its Q4 earnings. Here is a breakdown of the information Haleon PLC Sponsored ADR presented to its investors.
Haleon PLC is a global leader in consumer health, specializing in oral health, vitamins, minerals and supplements, pain relief, respiratory health, and digestive health, with a strong portfolio of trusted brands like Sensodyne and Centrum. The company has reported robust financial performance for the year ending December 2024, with a 5.0% organic revenue growth and a 9.8% increase in organic operating profit. Key highlights include strong cash flow, reduced net debt, and a proposed 10% increase in total full-year dividend. Haleon also announced a £500m allocation for share buybacks in 2025. The company achieved high-single-digit organic profit growth while investing in brand development and R&D. The company’s strategic focus on expanding its market share is evident, with 71% of its business gaining or maintaining market share. Looking forward, Haleon is optimistic about its growth prospects, expecting organic revenue growth of 4-6% in 2025, with organic operating profit growth anticipated to surpass revenue growth. The company plans to continue its disciplined capital allocation strategy, balancing growth investments with shareholder returns.